Connect Biopharma Holdings Ltd has 11 Schedule 13D or 13G filings on record since 2025-07-21. 3 holders' latest filing reports 5% or more of ordinary shares, par value $0.000174. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Panacea Innovation Limited | 21.2% | 13,160,000 | SCHEDULE 13D/A, 2026-04-01 | 2026-03-31 |
| Wubin Pan | 9.6% | 6,026,813 | SCHEDULE 13G, 2026-04-14 | 2026-04-14 |
| Ikarian Capital, LLC | 6.9% | 4,338,534 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Wei Zheng | 4% | 2,520,359 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
Panacea Innovation Limited
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Securities Purchase Agreement On March 29, 2026, Panacea Venture Healthcare Fund II, L.P., together with certain other investors, entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, pursuant to which the Issuer agreed to sell an aggregate of 6,130,000 Ordinary Shares (the "Offering"). Pursuant to the Securities Purchase Agreement, Panacea Venture Healthcare Fund II, L.P. purchased 1,160,000 Ordinary Shares at a price of $3.45 per Ordinary Share. The Offering closed on March 31, 2026. Pursuant to the Securities Purchase Agreement, the Issuer agreed to file a registration statement with the Securities and Exchange Commission within 45 days after the closing of the Offering covering the resale of the Ordinary Shares issued to the investors pursuant to the Securities Purchase Agreement. Additionally, James Huang has agreed not to sell or otherwise dispose of any Ordinary Shares held by him for a period ending 45 days after the closing of the Offering (the "Lock-up Agreement") without first obtaining the written consent of the Placement Agents (as defined in the Securities Purchase Agreement). The Lock-up Agreement is included as Exhibit A to the Securities Purchase Agreement. The foregoing description of the Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Securities Purchase Agreement, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-01; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | Panacea Innovation Limited | 25.1% | SCHEDULE 13D/A |
| 2025-11-26 | Panacea Innovation Limited | 21.5% | SCHEDULE 13D/A |
| 2025-11-28 | Wei Zheng | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 8.8% | SCHEDULE 13G |
| 2026-02-17 | Zheng Wei | 9% | SCHEDULE 13G/A |
| 2026-02-17 | Wubin Pan | 10.8% | SCHEDULE 13G/A |
| 2026-04-01 | Panacea Innovation Limited | 21.2% | SCHEDULE 13D/A |
| 2026-04-14 | Wubin Pan | 9.6% | SCHEDULE 13G |
| 2026-05-15 | Wei Zheng | 6.2% | SCHEDULE 13G/A |
| 2026-08-14 | Ikarian Capital, LLC | 6.9% | SCHEDULE 13G/A |
| 2026-08-14 | Wei Zheng | 4% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Connect Biopharma Holdings Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.